This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Analysts Estimate CVS Health (CVS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights CVS Health, Walgreens BootsAlliance, Rite Aid and Amazon
by Zacks Equity Research
CVS Health, Walgreens BootsAlliance, Rite Aid and Amazon have been highlighted in this Industry Outlook article.
3 Retail Pharmacy and Drugstore Stocks to Watch in a Growing Industry
by Urmimala Biswas
Zacks Retail Pharmacy and Drugstore industry players like CVS, WBA and RAD are likely to gain on the strength of their digital pharmacies.
CVS Health (CVS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $73.25, moving -1.29% from the previous trading session.
Rite Aid (RAD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rite Aid (RAD) delivered earnings and revenue surprises of -61.04% and 6.90%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
CVS Health (CVS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $74.92, moving -1.8% from the previous trading session.
CVS Health (CVS) Team Up to Treat Digestive Disorder Virtually
by Zacks Equity Research
CVS Health's (CVS) recent partnership with Oshi makes it possible for its members to receive coordinated virtual digestive treatment.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $77.54 in the latest trading session, marking a -0.27% move from the prior day.
Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
by Zacks Equity Research
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CVS Health's (CVS) New Initiatives Aid, Margin Woes Linger
by Zacks Equity Research
CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.
CVS Health (CVS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $74.70 in the latest trading session, marking a +0.82% move from the prior day.
Wall Street Bulls Look Optimistic About CVS Health (CVS): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
CVS Health (CVS) Nears Completion of $8B SGFY Acquisition
by Zacks Equity Research
According to CVS Health (CVS), Signify Health, a leading healthcare platform, is set to play a critical role in advancing its healthcare services strategy.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
by Zacks Equity Research
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Health (CVS) Stock Moves -1.52%: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $74.41, moving -1.52% from the previous trading session.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $75.83 in the latest trading session, marking a +0.57% move from the prior day.
Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Should Investors Buy Bristol Myers or CVS Stock Near 52-week Lows?
by Shaun Pruitt
Investors are often on the lookout for strong companies that may be undervalued and present lucrative long-term opportunities.
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $77.10 in the latest trading session, marking a +0.13% move from the prior day.
CVS Health (CVS) Down 14.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS), backed by the announcement of entering into a colossal $10.6-billion acquisition agreement to purchase Oak Street Health.
Is Trending Stock CVS Health Corporation (CVS) a Buy Now?
by Zacks Equity Research
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.